Reshef Tal, M.D., Ph.D., David B. Seifer, M.D., Aya Shohat-Tal, Ph.D., Richard V. Grazi, M.D., Henry E. Malter, Ph.D.
Volume 100, Issue 2, Pages 538-543, August 2013
To evaluate the relationship between transforming growth factor (TGF)-β1 and its receptor, soluble endoglin (sENG), in the serum and follicular fluid of women with polycystic ovarian syndrome (PCOS)
compared with that of non-PCOS normal ovulating women during controlled ovarian stimulation (COS).
Prospective case-control study.
Academic-affiliated assisted reproductive technology unit.
Fourteen PCOS and 14 matched non-PCOS control women undergoing COS.
Serum was collected on day 3 (baseline), day of hCG, and day of retrieval. Follicular fluid (FF) was collected on day of oocyte retrieval. ELISA was performed to determine TGF-β1 and sENG protein levels.
Main Outcome Measure(s):
Serum and FF levels of TGF-β1 and sENG.
Serum TGF-β1 did not change significantly during COS but was increased in PCOS compared with non-PCOS women on day 3 and days of hCG administration and oocyte retrieval. Serum sENG increased after hCG administration only in the non-PCOS control group. In addition, serum sENG was decreased in PCOS compared with non-PCOS control women on the days of hCG and retrieval. Accordingly, the bioavailability of TGF-β1 (TGF-β1/sENG ratio) was increased in women with PCOS compared with non-PCOS controls at all three time points. No differences in either factor were noted in FF between groups.
The increased TGF-β1 bioavailability in PCOS is not only due to increased TGF-β1 levels but also to decreased levels of its receptor, sENG. These data suggest that increased TGF-β1 bioavailability may contribute to the pathogenesis of PCOS and its increased risk for ovarian hyperstimulation.
Read the full text at: http://www.fertstert.org/article/S0015-0282(13)00518-9/fulltext